Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations ; day:11 ; month:8 ; year:2016 ; pages:1-10
Oncology and Therapy ; (11.8.2016), 1-10
- Creator
-
Francescon, Sara
- Contributor
-
Fornasier, Giulia
Baldo, Paolo
SpringerLink (Online service)
- DOI
-
10.1007/s40487-016-0028-9
- URN
-
urn:nbn:de:1111-2016090926714
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.20242024, 1:55 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Francescon, Sara
- Fornasier, Giulia
- Baldo, Paolo
- SpringerLink (Online service)
Other Objects (12)
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
Pharmacovigilance in oncology
Pharmacovigilance Considerations for Biosimilars in the USA
Current status and considerations on biosimilar in China
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Solution Oligonucleotide APIs: Regulatory Considerations
Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action
Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
Pharmacovigilance in oncology
Pharmacovigilance Considerations for Biosimilars in the USA
Current status and considerations on biosimilar in China
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Solution Oligonucleotide APIs: Regulatory Considerations
Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action
Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
Pharmacovigilance in oncology
Pharmacovigilance Considerations for Biosimilars in the USA
Current status and considerations on biosimilar in China
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Solution Oligonucleotide APIs: Regulatory Considerations
Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action
Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations